
Last update at 2026-01-30 15:53:44
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Income before tax | 12598.78M | 8161.88M | 8364.00M | 7790.48M | 5504.98M |
| Net income | 9275.83M | 5899.61M | 6106.90M | 3807.69M | 3581.47M |
| Total Revenue | 37492.10M | 34537.06M | 32517.20M | 32780.29M | 31988.62M |
| Gross Profit | 23353.58M | 20985.05M | 19668.50M | 18283.75M | 18041.89M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 41080.80M | 35566.18M | 33265.80M | 46332.78M | 31133.61M |
| Intangible assets | 133.30M | 235.54M | 340.91M | 344.97M | 433.64M |
| Other current assets | 692.17M | 666.34M | 300.40M | 40.34M | 57.23M |
| Deferred long term liab | - | - | - | - | - |
| Non current assets other | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Change in Cash | 4746.79M | 292.30M | -2512.50M | -1190.02M | 3003.78M |
| Operating Cash | 12899.10M | 5820.16M | 4842.30M | 8107.48M | 5779.25M |
| Free Cash Flow | 12668.90M | 5507.94M | 4401.90M | 7761.07M | 5336.99M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| GLAXO GlaxoSmithKline Pharmaceuticals Limited |
35.00 1.48% | 2401.60 | 406354.23 | 42.58 |
| PFIZER Pfizer Limited |
83.80 1.80% | 4751.40 | 222237.90 | 26.50 |
| SANOFICONR SANOFI CONS HEALTHC IND L |
-97.90 -2.23% | 4291.00 | 101612.67 | 46.61 |
| SANOFI Sanofi India Limited |
22.40 0.56% | 4037.60 | 95811.08 | 26.88 |
| MARKSANS Marksans Pharma Limited |
-2.46 -1.37% | 177.58 | 81052.87 | 23.02 |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.
GSK House, Mumbai, India, 400030
| Name | Title | Year Born |
|---|---|---|
| Mr. Bhushan Akshikar | Exec. VP of Gen. Medicines & MD | NA |
| Mr. Juby Chandy | Whole-Time Director & CFO | NA |
| Mr. Abhinav Kashyap | VP of Technology | NA |
| Mr. Ajay A. Nadkarni | VP of Admin. & Real Estate and Company Sec. | NA |
| Mr. Amit G. Pandey | Exec. VP of Legal | NA |
| Mr. Ransom D'Souza | Exec. VP of Communications & Gov. Affairs | NA |
| Mr. Chinmay Sharma | Exec. VP of HR | NA |
| Ms. Sukanya Choudhary | Exec. Vice-Pres of Regulatory Affairs | NA |
| Mr. Sougato Mitra | Head of Specialty | NA |
| Dr. Rashmi Hegde M.D. | Exec. VP of Medical Affairs & Country Medical Head of India | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.